1-3 of 3
Martine E.D. Chamuleau, MD PhD
Close
Sort by
Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-133820
Published: 2020
Journal Articles

Low CLIP Expression On Leukemic Blasts From AML Patients Is Essential for the Generation of Effective CD4 + T Cell Responses.

Marvin M. van Luijn, Martine E.D. Chamuleau, MD, PhD, James A. Thompson, Suzanne Ostrand-Rosenberg, PhD, Theresia M. Westers, PhD, Yuri Souwer, Gert J. Ossenkoppele, MD, PhD, S. Marieke van Ham, PhD, Arjan A. van de Loosdrecht, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 996.
https://doi.org/10.1182/blood.V114.22.996.996
Published: 2009
Journal Articles

Myeloid Leukemic Blasts Use the Endogenous HLA Class I Antigen Processing Machinery for Peptide Loading Onto HLA Class II Molecules: Implications for Immunotherapy.

Marvin M. van Luijn, Martine E.D. Chamuleau, MD, PhD, Maaike E. Ressing, PhD, Emmanuel J.H.J. Wiertz, PhD, Suzanne Ostrand-Rosenberg, PhD, Yuri Souwer, Adri Zevenbergen, Gert J. Ossenkoppele, MD, PhD, Arjan A. van de Loosdrecht, MD, PhD, S. Marieke van Ham, PhD
Journal: Blood
Blood (2009) 114 (22): 3114.
https://doi.org/10.1182/blood.V114.22.3114.3114
Published: 2009